+

WO2011085261A1 - Inhibiteurs de hedgehog - Google Patents

Inhibiteurs de hedgehog Download PDF

Info

Publication number
WO2011085261A1
WO2011085261A1 PCT/US2011/020593 US2011020593W WO2011085261A1 WO 2011085261 A1 WO2011085261 A1 WO 2011085261A1 US 2011020593 W US2011020593 W US 2011020593W WO 2011085261 A1 WO2011085261 A1 WO 2011085261A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
hydrogen
halogen
heteroaryl
Prior art date
Application number
PCT/US2011/020593
Other languages
English (en)
Inventor
Jean-Michel Vernier
John May
Patrick O'connor
William Ripka
Anthony Pinkerton
Original Assignee
Selexagen Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selexagen Therapeutics, Inc. filed Critical Selexagen Therapeutics, Inc.
Publication of WO2011085261A1 publication Critical patent/WO2011085261A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Definitions

  • Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary disease and disorders.
  • One embodiment provides a com ound having the structure of Formula (I):
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the compound of Formula (I) wherein G and G can not both be hydrogen.
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is halogen, C 1 -C 3 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, C 1 -C 3 alkyl, -CN, or -CF 3 ;
  • G is hydrogen, halogen, C 1 -C 3 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of halogen, -CN, alkyl, aryl, -O-aryl, -O- heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, -NH-heteroaryl, - NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 - (C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the compound of Formula (I) wherein X is S0 2 Me. Another embodiment provides the compound of Formula (I) wherein Z is a halogen.
  • Another embodiment provides the compound of Formula (I) wherein Y is a halogen.
  • Another embodiment provides the compound of Formula (I) wherein G is a hydrogen. Another embodiment provides the compound of Formula (I) wherein G 1 is an alkyl group. Another embodiment provides the compound of Formula (I) wherein Y is a chloro and G is a hydrogen. Another embodiment provides the compound of Formula (I) wherein Z is a
  • Y is a halogen
  • G is a hydrogen
  • G is an alkyl group.
  • One embodiment provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compond of Formula (I), or a stereoisomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein the compound of Formula (I) has the followin structure:
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • One embodiment provides a method of inhibiting the Hedgehog pathway in a cell comprising contacting the cell with an inhibitory concentration of a compound of Formula
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the cell is characterized by a patched loss-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a smoothened gain-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a constitutively active smoothened phenotype. Another embodiment provides the method wherein the cell is characterized by expression of Gli.
  • One embodiment provides a method of inhibiting the activity of smoothened protein in a cell comprising contacting the smoothened protein with an inhibitory concentration of a compound of Formula (I):
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the cell is characterized by a patched loss-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a smoothened gain-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a constitutively active smoothened phenotype. Another embodiment provides the method wherein the cell is characterized by expression of Gli.
  • One embodiment provides a method of inhibiting the transcriptional activity of Gli transcription factor in a cell comprising contacting the cell with an inhibitory concentration of a compound of Formula (I):
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF3, and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the cell is characterized by a patched loss-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a smoothened gain-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a constitutively active smoothened phenotype. Another embodiment provides the method wherein the cell is characterized by expression of Gli.
  • One embodiment provides a method of inhibiting G/z-mediated gene transcription in a cell comprising contacting the cell with an inhibitory concentration of a compound of Formula (I):
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the cell is characterized by a patched loss-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a smoothened gain-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a constitutively active smoothened phenotype. Another embodiment provides the method wherein the cell is characterized by expression of Gli.
  • One embodiment provides a method of treating a human disease or disorder mediated by Hedgehog pathway comprising administering to a patient a therapeutically effective amount of a composition comprising a compound of Formula (I), or a
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the disease or disorder is a proliferative disease.
  • the proliferative disease is selected from colon cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, and hepatocellular carcinoma.
  • the proliferative disease is selected from basal cell carcinoma, breast cancer, bone sarcoma, soft tissue sarcoma, chronic myeloid leukemia, acute myeloid leukemia, hematological cancer, meduUoblastoma, rhabdomyosaracoma, neuroblastoma, pancreatic cancer, breast carcinoma, meningioma, glioblastoma, astrocytoma, melanoma, stomach cancer, esophageal cancer, biliary tract cancer, prostate cancer, small cell lung cancer, non- small cell lung cancer, glial cell cancer, multiple myeloma, colon cancer, neuroectodermal tumor, neuroendocrine tumor, mastocytoma and Gorlin syndrome.
  • the proliferative disease is basal cell carcinoma.
  • One embodiment provides a method of treating a veterinary disease or disorder mediated by Hedgehog pathway comprising administering to a subject a therapeutically effective amount of a composition comprising a compound of Formula (I), or a
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the veterinary disease or disorder is a proliferative disease selected from mast cell tumors or osteosarcoma.
  • Figure 1 shows the dose-reponse of cyclopamine, a positive control, in the alkaline phosphatase assay described herein.
  • Figure 2 shows the dose-reponse of the compound of Example 1 in the alkaline phosphatase assay described herein.
  • One embodiment provides a com ound having the structure of Formula (I):
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • G and G can not both be hydrogen.
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is halogen, C 1 -C3 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 3 alkyl, -CN, or -CF 3 ;
  • G is hydrogen, halogen, Ci-C 3 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of halogen, -CN, alkyl, aryl, -O-aryl, -O- heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, -NH-heteroaryl, - NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 - (C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the compound of Formula (I) wherein X is S0 2 Me. Another embodiment provides the compound of Formula (I) wherein Z is a halogen.
  • Another embodiment provides the compound of Formula (I) wherein Y is a halogen.
  • Another embodiment provides the compound of Formula (I) wherein G is a hydrogen. Another embodiment provides the compound of Formula (I) wherein G 1 is an alkyl group. Another embodiment provides the compound of Formula (I) wherein Y is a chloro and G is a hydrogen. Another embodiment provides the compound of Formula (I) wherein Z is a
  • Y is a halogen
  • G is a hydrogen
  • G is an alkyl group.
  • the compounds of Formula (I) have the structures shown in Table 1.
  • a compound of Formula (I) is selected from the structures shown below as examples 6-67.
  • Example 59 Example 60
  • Example 61 Example 61
  • Example 65 Example 66 Example 67
  • Amino refers to the -NH 2 radical.
  • Cyano refers to the -CN radical.
  • Niro refers to the -N0 2 radical.
  • Oxa refers to the -O- radical.
  • Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C 1 -C 15 alkyl).
  • an alkyl comprises one to thirteen carbon atoms (e.g., C 1 -C 13 alkyl).
  • an alkyl comprises one to eight carbon atoms (e.g., C ⁇ -C % alkyl).
  • an alkyl comprises one to five carbon atoms (e.g., C 1 -C 5 alkyl).
  • an alkyl comprises one to four carbon atoms (e.g., C 1 -C4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., C 1 -C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., C 1 -C 2 alkyl).
  • the alkyl is attached to the rest of the molecule by a single bond, for example, methyl (Me), ethyl (Et), n-propyl, 1 -methyl ethyl (z ' so-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like.
  • an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR a , -SR a , -OC(0)-R a , -N(R a ) 2 , -C(0)R a , -C(0)OR a , -C(0)N(R a ) 2 , -N(R a )C(0)OR a , -N(R a )C(0)R a , -N(R a )S(0),R a (where t is 1 or 2), -S(0),OR a (where t is 1 or 2) and -S(0) t N(R a ) 2 (where t is 1 or 2) where each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalky
  • an alkyl group is optionally a fluorinated or perfluorinated alkyl group, such as CF 3 , CF 2 CF 3 , CH 2 F, CHF 2 , CH 2 CF 3 and the like.
  • alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having from two to twelve carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms. The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-l-enyl (i.e., allyl), but-l-enyl, pent-l-enyl, penta-l,4-dienyl, and the like.
  • ethenyl i.e., vinyl
  • prop-l-enyl i.e., allyl
  • but-l-enyl pent-l-enyl, penta-l,4-dienyl, and the like.
  • an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR a , -SR a , -OC(0)-R a , -N(R a ) 2 , -C(0)R a , -C(0)OR a , -C(0)N(R a ) 2 , -N(R a )C(0)OR a , -N(R a )C(0)R a , -N(R a )S(0) t R a (where t is 1 or 2), -S(0),OR a (where t is 1 or 2) and -S(0) t N(R a ) 2 (where t is 1 or 2) where each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclyl
  • Alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to twelve carbon atoms.
  • an alkynyl comprises two to eight carbon atoms.
  • an alkynyl has two to four carbon atoms.
  • the alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
  • an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR a , -SR a , -OC(0)-R a , -N(R a ) 2 , -C(0)R a , -C(0)OR a , -C(0)N(R a ) 2 , -N(R a )C(0)OR a , -N(R a )C(0)R a , -N(R a )S(0) t R a (where t is 1 or 2), -S(0),OR a (where t is 1 or 2) and -S(0),N(R a ) 2 (where t is 1 or 2) where each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclyl
  • Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon in the alkylene chain or through any two carbons within the chain.
  • an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR a , - SR a , -OC(0)-R a , -N(R a ) 2 , -C(0)R a , -C(0)OR a , -C(0)N(R a ) 2 , -N(R a )C(0)OR a ,
  • alkenylene or "alkenylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one double bond and having from two to twelve carbon atoms, for example, ethenylene, propenylene, n-butenylene, and the like.
  • the alkenylene chain is attached to the rest of the molecule through a double bond or a single bond and to the radical group through a double bond or a single bond.
  • the points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
  • an alkenylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR a , -SR a , -OC(0)-R a , -N(R a ) 2 , -C(0)R a , -C(0)OR a , -C(0)N(R a ) 2 , -N(R a )C(0)OR a , -N(R a )C(0)R a , -N(R a )S(0),R a (where t is 1 or 2), -S(0),OR a (where t is 1 or 2) and -S(0),N(R a ) 2 (where t is 1 or 2) where each R a is independently hydrogen, alkyl,
  • Aryl refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
  • the aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from six to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ -electron system in accordance with the Huckel theory.
  • Aryl groups include, but are not limited to, groups such as phenyl, fluorenyl, and naphthyl.
  • aryl or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R b -OR a , -R b -OC(0)-R a , -R b -N(R a ) 2 , -R b -C(0)R a , -R
  • Aralkyl refers to a radical of the formula -R c -aryl where R c is an alkylene chain as defined above, for example, benzyl, diphenylmethyl and the like.
  • the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
  • the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
  • alkenyl refers to a radical of the formula -R d -aryl where R d is an alkenylene chain as defined above.
  • the aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group.
  • the alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
  • Aralkynyl refers to a radical of the formula -R e -aryl, where R e is an alkynylene chain as defined above.
  • the aryl part of the aralkynyl radical is optionally substituted as described above for an aryl group.
  • the alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.
  • Carbocyclyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused or bridged ring systems, having from three to fifteen carbon atoms.
  • a carbocyclyl comprises three to ten carbon atoms.
  • a carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is attached to the rest of the molecule by a single bond.
  • Carbocyclyl is optionally saturated, (i.e., containing single C-C bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds.)
  • a fully saturated carbocyclyl radical is also referred to as "cycloalkyl.”
  • monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • An unsaturated carbocyclyl is also referred to as
  • cycloalkenyl examples include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
  • Polycyclic carbocyclyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
  • carbocyclyl is meant to include carbocyclyl radicals that are optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R b -OR a , -R b -SR a ,
  • each R a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl
  • each R b is independently a direct bond or a straight or branched alkylene or alkenylene chain
  • R c is a straight or branched alkylene or alkenylene chain
  • Carbocyclylalkyl refers to a radical of the formula -R c -carbocyclyl where R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical is optionally substituted as defined above.
  • Halo or "halogen” refers to bromo, chloro, fluoro or iodo substituents.
  • Fluoroalkyl refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trif uoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, l-fluoromethyl-2-fluoroethyl, and the like.
  • the alkyl part of the fluoroalkyl radical is optionally substituted as defined above for an alkyl group.
  • Heterocyclyl refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, and includes fused or bridged ring systems. The heteroatoms in the heterocyclyl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocyclyl radical is partially or fully saturated. The heterocyclyl is attached to the rest of the molecule through any atom of the ring(s). Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl,
  • heterocyclyl is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl alkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R b -OR a , -R b -SR a , -R b -OC(0)-R a , -R b -N(R a ) 2 , -R b -OR a , -R b
  • N-heterocyclyl or “N-attached heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the
  • heterocyclyl radical An N-heterocyclyl radical is optionally substituted as described above for heterocyclyl radicals.
  • Examples of such N-heterocyclyl radicals include, but are not limited to, 1-morpholinyl, 1 -piperidinyl, 1 -piperazinyl, 1 -pyrrolidinyl, pyrazolidinyl, imidazolinyl, and imidazolidinyl.
  • C-heterocyclyl or “C-attached heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one heteroatom and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a carbon atom in the heterocyclyl radical.
  • a C-heterocyclyl radical is optionally substituted as described above for heterocyclyl radicals. Examples of such C-heterocyclyl radicals include, but are not limited to, 2-morpholinyl, 2- or 3- or 4-piperidinyl, 2-piperazinyl, 2- or 3 -pyrrolidinyl, and the like.
  • Heterocyclylalkyl refers to a radical of the formula -R c -heterocyclyl where R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heterocyclylalkyl radical is optionally substituted as defined above for an alkylene chain.
  • the heterocyclyl part of the heterocyclylalkyl radical is optionally substituted as defined above for a heterocyclyl group.
  • Heteroaryl refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur.
  • the heteroaryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ -electron system in accordance with the Huckel theory.
  • Heteroaryl includes fused or bridged ring systems.
  • the heteroatom(s) in the heteroaryl radical is optionally oxidized.
  • heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
  • heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl,
  • heteroaryl is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R b -OR a , -R b -SR a ,
  • each R a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl
  • each R b is independently a direct bond or a straight or branched alkylene or alkenylene chain
  • R c is a straight or branched alkylene or alkenylene chain
  • N-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical.
  • An N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
  • C-heteroaryl refers to a heteroaryl radical as defined above and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom in the heteroaryl radical.
  • a C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
  • Heteroarylalkyl refers to a radical of the formula -R c -heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain.
  • the heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
  • the compounds, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
  • the compounds described herein contain olefmic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both Z and E geometric isomers (e.g., cis or trans).
  • Z and E geometric isomers e.g., cis or trans
  • all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included.
  • a “stereoisomer” refers to the relationship between two or more compounds made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not superimposable.
  • the term “enantiomer” refers to two
  • stereoisomers that are nonsuperimposeable mirror images of one another. It is contemplated that the various stereoisomers of the compounds disclosed herein, and mixtures thereof, are within the scope of the present disclosure and specifically includes enantiomers.
  • a "tautomer” refers to a compound wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible.
  • the compounds presented herein may exist as tautomers. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Some examples of tautomeric equilibrium are shown below.
  • Scheme 1 illustrates the synthesis of benzamide hedgehog inhibitors.
  • Methyl 2- amino-4-methylsulfonylbenzoate is subjected to a diazotization reaction in the presence of a halide salt, such as potassium iodide, to give the 2-halo compound.
  • a halide salt such as potassium iodide
  • Hydrolysis of the ester followed by coupling with a thiazole-substituted aniline gives the advanced benzamide intermediate.
  • a variety of cross coupling reactions (such as those described by D. A.
  • Scheme 2 illustrates the synthesis of benzamide hedgehog inhibitors. Coupling of the acid with a substituted 3-iodoaniline gives the 3-iodobenzamide. A palladium catalyzed cross coupling reaction between thiazole boronic acid or a thiazole stannane and the 3- iodobenzamide gives the benzamide hedgehog inhibitor.
  • Scheme 3 illustrates the synthesis of benzamide hedgehog inhibitors.
  • Methyl 4- methylsulfonylbenzoate derivatives are subjected to cross coupling reactions (such as those described by D. A. Evans, et al, Tetrahedron Letters, 1998, 39, 2937-2940; D. M. T. Chan, et al, Tetrahedron Lett., 1998, 39, 2933-2936; P. Y. S. Lam, et al, Tetrahedron Lett., 1998, 39, 2941-2944; Y.-C. Wong, et al, Org. Lett., 2006, 8, 5613-5616; S. A. Weissman, D. Zewge, C.
  • Scheme 4 further illustrates the synthesis of thiazole based Hedgehog inhibitors based on amide bond formation with hexafluorophosphate (o-(7-azabenzo- triazol-l-yl)- 1 , 1 ,3,3-tetramethyluronium (HATU).
  • HATU hexafluorophosphate
  • Scheme 5 illustrates the general synthesis of the aniline intermediate that can be coupled to the appropriate carboxylic acid to form the desired product.
  • cancer stem cells characteristics, commonly referred to as cancer stem cells, within human primary tumor samples. These newly described cancer stem cells replicate more slowly, are more resistant to conventional chemotherapy, and their survival appears to be a major contributor to tumor re-growth following surgery and/or chemotherapy. In contrast to bulk tumor cells, cancer stem cells appear to be more reliant on embryonic pathways for their proliferation and survival traits.
  • the Hedgehog Pathway Several key signaling pathways (e.g. Hedgehog, Notch, Wnt) are involved in most processes essential to the normal development of an embryo.
  • the Hedgehog pathway was initially discovered in Drosophila by Dr. Eric Wieschaus and Dr. Christiane Nusslein-Volhard, and is a major regulator for cell differentiation, tissue polarity and cell proliferation. It is also becoming clear that the Hedgehog pathway may play a crucial role in tumorigenesis when reactivated in adult tissues through either mutation or other mechanisms. It is thought that the Hedgehog pathway is an important driver of tumorigenesis in at least l/3rd of all types of cancer.
  • Hh over expression is associated with at least pancreatic, colon, gastric, liver and prostate cancer.
  • the estimated incidence of cancers with ligand dependent activation of Hh in the US is > 200,000 cases annually and approximately 10-fold higher worldwide.
  • Human Sonic Hedgehog protein (SHh) is synthesized as a 45 kDa precursor protein that undergoes autocleavage to yield a 20 kDa fragment that is responsible for normal Hedgehog pathway signaling.
  • Hedgehog signal is thought to be relayed through the 12 transmembrane domain protein, Patched (Ptc) and the 7
  • Smo transmembrane domain protein, Smoothened (Smo).
  • Ptc serves as a negative regulatory of Smo activity.
  • the binding of SHh to Ptc inhibits the normal inhibitory effect of Ptc on Smo allowing Smo to transduce the SHh signal across the plasma membrane.
  • the signal cascade initiated by Smo results in the activation of Gli transcription factors that migrate to the nucleus where they control target transcription factors effecting cell growth and differentiation in embryonic cells and where uncontrolled activation in adult cells is associated with malignancies.
  • One embodiment provides a method of inhibiting the Hedgehog pathway in a cell comprising contacting the cell with an inhibitory concentration of a compound of Formula
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF , and wherein G and G can not both be hydrogen; and Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the cell is characterized by a patched loss-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a smoothened gain-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a constitutively active smoothened phenotype. Another embodiment provides the method wherein the cell is characterized by expression of Gli.
  • One embodiment provides a method of inhibiting the activity of smoothened protein in a cell comprising contacting the smoothened protein with an inhibitory concentration of a compound of Formula (I):
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the cell is characterized by a patched loss-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a smoothened gain-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a constitutively active smoothened phenotype. Another embodiment provides the method wherein the cell is characterized by expression of Gli.
  • One embodiment provides a method of inhibiting the transcriptional activity of Gli transcription factor in a cell comprising contacting the cell with an inhibitory concentration of a compound of Formula (I):
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the cell is characterized by a patched loss-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a smoothened gain-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a constitutively active smoothened phenotype. Another embodiment provides the method wherein the cell is characterized by expression of Gli.
  • One embodiment provides a method of inhibiting G/z-mediated gene transcription in a cell comprising contacting the cell with an inhibitory concentration of a compound of Formula (I):
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the cell is characterized by a patched loss-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a smoothened gain-of-function phenotype. Another embodiment provides the method wherein the cell is characterized by a constitutively active smoothened phenotype. Another embodiment provides the method wherein the cell is characterized by expression of Gli.
  • One embodiment provides a method of treating a human disease or disorder mediated by Hedgehog pathway comprising administering to a patient a therapeutically effective amount of a composition comprising a compound of Formula (I), or a
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the disease or disorder is a proliferative disease.
  • the proliferative disease is selected from colon cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, and hepatocellular carcinoma.
  • the proliferative disease is selected from basal cell carcinoma, breast cancer, bone sarcoma, soft tissue sarcoma, chronic myeloid leukemia, acute myeloid leukemia, hematological cancer, medulloblastoma, rhabdomyosaracoma, neuroblastoma, pancreatic cancer, breast carcinoma, meningioma, glioblastoma, astrocytoma, melanoma, stomach cancer, esophageal cancer, biliary tract cancer, prostate cancer, small cell lung cancer, non- small cell lung cancer, glial cell cancer, multiple myeloma, colon cancer, neuroectodermal tumor, neuroendocrine tumor, mastocytoma and Gorlin syndrome.
  • the proliferative disease is basal cell carcinoma.
  • One embodiment provides a method of treating a veterinary disease or disorder mediated by Hedgehog pathway comprising administering to a subject a therapeutically effective amount of a composition comprising a compound of Formula (I), or a
  • W is O or S
  • X is S0 2 Me, CI, or -OMe
  • Y is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 ;
  • G 1 is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF ;
  • G is hydrogen, halogen, Ci-C 6 alkyl, -CN, or -CF 3 , and wherein G and G can not both be hydrogen;
  • Z is selected from the group consisting of hydrogen, halogen, -CN, alkyl, -O-alkyl, aryl, -O-aryl, -O-heteroaryl, -CH 2 -aryl, -CH 2 -heteroaryl, -NH-aryl, -S0 2 -aryl, - NH-heteroaryl, -NH-alkyl, -CH 2 -NH-alkyl, -CH 2 -N(alkyl) 2 , -CH 2 -(N-linked heterocycle), -CH 2 -(C-linked heterocycle), N-linked heterocycle, and C-linked heterocycle.
  • Another embodiment provides the method wherein the veterinary disease or disorder is a proliferative disease selected from mast cell tumors or osteosarcoma.
  • Example 1 2-chloro-4-(methylsulfonyl)-N-(3-(2-methylthiazol-4- yl)phenyl)benzamide
  • Step 1 Methyl 2-(bromomethyl)-4-methoxybenzoate
  • Step 2 methyl 4-methoxy-2-(morpholinomethyl)benzoate
  • Step 3 4-methoxy-2-(morpholinomethyl)benzoic acid
  • Step 4 4-methoxy-N-(3-(2-methylthiazol-4-yl)phenyl)-2-
  • Example 4 4-methoxy-2-((4-methylpiperazin-l-yl)methyl)-N-(3-(2- methylthiazol-4-yl)phenyl)benzamide
  • Example 4 is synthesized using the chemistry described for example 3 according to the followin synthetic scheme.
  • Example 5 2-((2-hydroxyethylamino)methyl)-4-methoxy-N-(3-(2- methylthiazol-4-yl)phenyl)benzamide
  • example 5 is synthesized using the chemistry described for example 3 according to the following synthetic scheme:
  • Example 65 Example 66 Example 67
  • Method A Mouse C3H10T1/2 (CCL-226TM) or M2-10B4 (CRL-1972TM) cells obtained from the American Type Tissue Culture Collection (Maryland, USA) were cultured to 60- 80% confluence in Dulbecco's modified Eagle's Medium (C3H10T1/2 cells) containing heat-inactivated 10% fetal bovine serum or RPMI-1640 media (M2-10B4 cells) containing heat-inactivated 10% fetal bovine serum. Cell cultures were maintained in 10 U/mL penicillin, 100 ⁇ g/mL streptomycin and 2 mM glutamine.
  • Control vehicle DMSO
  • compound dissolved in 100% DMSO were serially added to individual wells, 30 minutes prior to the addition of Control Buffer or Recombinant Mouse Sonic Hedgehog (Shh-N, CF, 461-SH-025/CF, R&D Systems, Minnesota, USA) to final concentration of 2 ⁇ g/mL.
  • pNPP p-nitrophenyl phosphate
  • cell culture media was carefully aspirated from the wells of the 96-well microtiter plates and cells gently washed with phosphate-buffered saline, pH 7.4 (PBS). Following removal of PBS, cells were lysed in 50 ⁇ , RIPA lysis buffer and alkaline phosphatase activity assayed following addition of 50 pNPP reaction mixture for 30 minutes during which reagents were mixed by gently shaking of the plates.
  • Modified Method A An additional method to assess inhibition of hedgehog pathway signaling was also applied in which 100 nM of the smoothened agonist, purmorphamine (Stemgent, California) was added to confluent C3H10T1/2 cells instead of recombinant sonic hedgehog protein and 72 hours after co-incubation with compounds alkaline phosphatase activity was assayed using the alkaline phosphatase assay kit from Bio Assay Systems (Haywood, California).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés, des compositions pharmaceutiques et des procédés d'inhibition de la voie de signalisation Hedgehog. Lesdits composés, compositions pharmaceutiques et procédés peuvent être utilisés dans le traitement de maladies et d'affections touchant l'homme ou l'animal.
PCT/US2011/020593 2010-01-08 2011-01-07 Inhibiteurs de hedgehog WO2011085261A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29331510P 2010-01-08 2010-01-08
US61/293,315 2010-01-08

Publications (1)

Publication Number Publication Date
WO2011085261A1 true WO2011085261A1 (fr) 2011-07-14

Family

ID=44305812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/020593 WO2011085261A1 (fr) 2010-01-08 2011-01-07 Inhibiteurs de hedgehog

Country Status (1)

Country Link
WO (1) WO2011085261A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174949B2 (en) 2010-01-07 2015-11-03 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2018002437A1 (fr) 2016-06-29 2018-01-04 Orion Corporation Dérivés de benzodioxane et leur utilisation pharmaceutique
WO2018121610A1 (fr) * 2016-12-27 2018-07-05 山东大学 Inhibiteur de la voie hedgehog pour souche smoothened mutante
WO2020132648A1 (fr) * 2018-12-20 2020-06-25 Amgen Inc. Inhibiteurs de kif18a
WO2020132651A1 (fr) * 2018-12-20 2020-06-25 Amgen Inc. Inhibiteurs de kif18a
US12084420B2 (en) 2021-08-26 2024-09-10 Volastra Therapeutics, Inc. Indoline compounds for inhibiting KIF18A

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058302A1 (en) * 2001-11-12 2006-03-16 Pfizer Inc. Benzamide, heteroarylamide and reverse amides
WO2009027746A1 (fr) * 2007-08-31 2009-03-05 Astrazeneca Ab Amides hétérocycliques utiles dans le traitement du cancer et du psoriasis
EP1725544B1 (fr) * 2004-03-09 2009-05-27 Boehringer Ingelheim Pharmaceuticals Inc. 3-[4-heterocyclyl -1,2,3,-triazol-1-yl]-n-aryl-benzamides en tant qu'inhibiteurs de la production de cytokines pour le traitement de maladies inflammatoires
US20090209573A1 (en) * 2004-10-28 2009-08-20 Irm Llc Compounds and compositions as hedgehog pathway modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058302A1 (en) * 2001-11-12 2006-03-16 Pfizer Inc. Benzamide, heteroarylamide and reverse amides
EP1725544B1 (fr) * 2004-03-09 2009-05-27 Boehringer Ingelheim Pharmaceuticals Inc. 3-[4-heterocyclyl -1,2,3,-triazol-1-yl]-n-aryl-benzamides en tant qu'inhibiteurs de la production de cytokines pour le traitement de maladies inflammatoires
US20090209573A1 (en) * 2004-10-28 2009-08-20 Irm Llc Compounds and compositions as hedgehog pathway modulators
WO2009027746A1 (fr) * 2007-08-31 2009-03-05 Astrazeneca Ab Amides hétérocycliques utiles dans le traitement du cancer et du psoriasis

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174949B2 (en) 2010-01-07 2015-11-03 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2018002437A1 (fr) 2016-06-29 2018-01-04 Orion Corporation Dérivés de benzodioxane et leur utilisation pharmaceutique
CN110099900B (zh) * 2016-12-27 2022-12-02 山东大学 针对Smoothened突变株的刺猬通路抑制剂
CN110099900A (zh) * 2016-12-27 2019-08-06 山东大学 针对Smoothened突变株的刺猬通路抑制剂
WO2018121610A1 (fr) * 2016-12-27 2018-07-05 山东大学 Inhibiteur de la voie hedgehog pour souche smoothened mutante
WO2020132648A1 (fr) * 2018-12-20 2020-06-25 Amgen Inc. Inhibiteurs de kif18a
WO2020132651A1 (fr) * 2018-12-20 2020-06-25 Amgen Inc. Inhibiteurs de kif18a
CN113226473A (zh) * 2018-12-20 2021-08-06 美国安进公司 Kif18a抑制剂
JP2022513972A (ja) * 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
JP2022514268A (ja) * 2018-12-20 2022-02-10 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
JP7407196B2 (ja) 2018-12-20 2023-12-28 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
TWI844602B (zh) * 2018-12-20 2024-06-11 美商安進公司 Kif18a抑制劑
US12054476B2 (en) 2018-12-20 2024-08-06 Amgen Inc. KIF18A inhibitors
AU2019403486B2 (en) * 2018-12-20 2025-04-24 Amgen Inc. KIF18A inhibitors
US12084420B2 (en) 2021-08-26 2024-09-10 Volastra Therapeutics, Inc. Indoline compounds for inhibiting KIF18A

Similar Documents

Publication Publication Date Title
US10807956B2 (en) Histone demethylase inhibitors
CA2785204C (fr) Inhibiteurs de la voie hedgehog
JP6768857B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
AU2015253040A1 (en) Inhibitors of lysine specific demethylase-1
AU2015284197A1 (en) Inhibitors of lysine specific demethylase-1
WO2011085261A1 (fr) Inhibiteurs de hedgehog
WO2011014888A1 (fr) Inhibiteurs inédits de la voie de signalisation hedgehog
WO2016044138A1 (fr) Inhibiteurs de l'histone déméthylase
WO2024259060A1 (fr) Inhibiteurs de la kinase met

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11732244

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11732244

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载